moclobemide has been researched along with Dysthymic Disorder in 6 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Dysthymic Disorder: Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors compared the outcomes of 35 outpatients with dysthymic disorder randomized to receive either treatment with moclobemide and interpersonal therapy (IPT) or moclobemide and routine clinical management." | 9.09 | A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. ( de Mello, MF; Menezes, PR; Myczcowisk, LM, 2001) |
| "An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R)." | 9.08 | Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. ( Amrein, R; Stabl, M; Versiani, M, 1997) |
| "We report on the case of female patient with chronic dysthymia, who took moclobemide at 300 mg/day throughout her first pregnancy." | 7.71 | Moclobemide in pregnancy. ( Rybakowski, JK, 2001) |
| "The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD." | 6.40 | Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. ( Versiani, M, 1998) |
| "The authors compared the outcomes of 35 outpatients with dysthymic disorder randomized to receive either treatment with moclobemide and interpersonal therapy (IPT) or moclobemide and routine clinical management." | 5.09 | A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. ( de Mello, MF; Menezes, PR; Myczcowisk, LM, 2001) |
| "An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R)." | 5.08 | Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. ( Amrein, R; Stabl, M; Versiani, M, 1997) |
| "We report on the case of female patient with chronic dysthymia, who took moclobemide at 300 mg/day throughout her first pregnancy." | 3.71 | Moclobemide in pregnancy. ( Rybakowski, JK, 2001) |
| "The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD." | 2.40 | Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. ( Versiani, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Versiani, M | 2 |
| Amrein, R | 1 |
| Stabl, M | 1 |
| Montgomery, SA | 1 |
| Bekaroğlu, M | 1 |
| Değer, O | 1 |
| Karahan, SC | 1 |
| Bilici, M | 1 |
| Soylu, C | 1 |
| Orem, A | 1 |
| de Mello, MF | 1 |
| Myczcowisk, LM | 1 |
| Menezes, PR | 1 |
| Rybakowski, JK | 1 |
2 reviews available for moclobemide and Dysthymic Disorder
| Article | Year |
|---|---|
Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Comor | 1998 |
Social phobia: diagnosis, severity and implications for treatment.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Behavior Therapy; Benzamides; Benzodiazepines; Child | 1999 |
2 trials available for moclobemide and Dysthymic Disorder
| Article | Year |
|---|---|
Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Consti | 1997 |
A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder.
Topics: Adult; Antidepressive Agents; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Moclobemide; Pa | 2001 |
2 other studies available for moclobemide and Dysthymic Disorder
| Article | Year |
|---|---|
Effects of antidepressant treatments on polymorphonuclear elastase levels in patients with depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biomarkers; Depressive Disorder, Maj | 2000 |
Moclobemide in pregnancy.
Topics: Adult; Dysthymic Disorder; Female; Humans; Moclobemide; Pregnancy; Pregnancy Complications; Pregnanc | 2001 |